RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)

US9970005B2 · kind B2 · utility

Assignee

• Sirna Therapeutics, Inc. · US

Inventors

• Mark Cancilla · Philadelphia, US
• James J. Cunningham · Devon, US
• William Michael Flanagan · Menlo Park, US
• Henry J. Haringsma · San Francisco, US
• Denise M. Kenski · San Francisco, US
• Matthew G. Stanton · Marlton, US
• Steven M. Stirdivant · Cary, US
• Aarron T. Willingham · San Francisco, US

Key dates

• Filing date: Dec 30, 2015
• Grant date: May 15, 2018
• Expiry date: Dec 30, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/51
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.